Director General Pharmacology

Dept of Drug Discovery Science at Boehringer-Ingelheim Pharma GmbH & Co KG

Brian Guth is director of General Pharmacology in the department of Drug Discovery Science at Boehringer-Ingelheim Pharma GmbH & Co KG in Biberach an der Riss, Germany. He also maintains an academic affiliation at the Medical School of the University of Essen, where he received his venia legendi in pathophysiology in 1996. Prior to his time in Germany, he was on the faculty of the School of Medicine at the University of California, San Diego in the Division of Cardiology where he directed the Seaweed Canyon Cardiovascular Laboratory after receiving his Ph.D. in Physiology and Pharmacology in 1983. Brian’s work in San Diego centered on cardiac contractile function and the control of the coronary circulation during acute and chronic regional myocardial ischemia. More recently he was named Extraordinary Professor at the North-West University’s Pre-clinical Drug Development Platform (PCDDP) in Potchefstroom, South Africa.

Brian joined Boehringer-Ingelheim in 1991 and spent the first few years working in thromboembolic research until taking over his present position in 1997. His group is responsible for profiling and qualifying drug candidates for development through the use of a battery of pharmacological and physiological tests interrogating a variety of physiological functions. His group has been a leading advocate of the use of telemetry-based data acquisition approaches in cardiovascular models using various animal species. Brian is a founding member of the Safety Pharmacology Society and has served as President of the Society in 2007-2008. He has also been active in consortium based projects sponsored by ILSI/HESI, examining translational aspects of animal models of cardiac function to the clinic.